" /> Autologous TGFbRII-4-1BB CSR-armored HPV16/52 E7-specific HLA-A*02:01-restricted TCR T-lymphocytes SCG142 - CISMeF





Preferred Label : Autologous TGFbRII-4-1BB CSR-armored HPV16/52 E7-specific HLA-A*02:01-restricted TCR T-lymphocytes SCG142;

NCIt synonyms : Autologous HPV16 E7/HPV52 E7-specific TCR-expressing T-lymphocytes SCG142; Autologous HPV16/52 E7-specific T-cell Receptor-engineered T-cells SCG142; Autologous HPV-specific TCR T-cells SCG142; Autologous TCR-T Cells SCG142;

NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted human papillomavirus type 16 (HPV16) and 52 (HPV52) isoform E7 protein and armored with a transforming growth factor (TGF) beta receptor type 2 (TGFbetaRII; TGFbRII)-tumor necrosis factor receptor superfamily member 9 (TNFRSF9; 4-1BB; CD137) chimeric switch receptor (CSR), with potential immunomodulating and antineoplastic activities. Upon re-introduction into the patient, the autologous TGFbRII-4-1BB CSR-armored HPV16/52 E7-specific HLA-A*02:01-restricted TCR T-lymphocytes SCG142 targets and binds to HPV16 E7- and HPV52 E7-expressing tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 E7 and HPV52 E7 antigen. HPV16 E7 and HPV52 E7, cell surface glycoproteins and tumor-associated antigens (TAAs), are overexpressed in various HPV-mediated cancers. The TGFbRII-4-1BB CSR targets and binds to TGFbRII, prevents TGFbRII signaling and, instead, promotes signaling through 4-1BB, which results in the stimulation of T-lymphocytes and enhanced tumor cell killing. This overcomes the immunosuppressive effects of TGFb signaling in the tumor microenvironment (TME) by converting suppressive signaling into a co-stimulatory signal.;

Molecule name : SCG 142; SCG-142;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
30/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.